Open Tender for Injection Infliximab,Tablet Mycophenolate sodium,Capsule Tacrolimus zero point five mg,Capsule Tacr in JHANSI, UTTAR PRADESH

The eligibility requirements include being a registered entity with the capability to fulfill the tender's specifications. Specifically, bidders must demonstrate experience in supplying pharmaceutical products and provide documentation validating their past performance. There are special provisions for Micro, Small, and Medium Enterprises (MSEs) that may permit exemptions from certain criteria.

Bidders must submit several crucial certificates, including an OEM Authorization Certificate and documents demonstrating compliance with the BoQ specifications. Evidence of past performance and bidder turnover documentation is also essential to verify eligibility. Failure to provide necessary certificates may lead to disqualification from the tender process.

Bidders must use the designated electronic platform for submission. All necessary documents, such as experience criteria, OEM authorization, and additional documentation as specified in the ATC must be uploaded in the required formats. It’s critical to follow the guidelines for successful submission to ensure the bid is considered.

The technical specifications for the products, including drugs like Injection Infliximab and various capsules, are outlined meticulously in the linked documents. Bidders are urged to review all specifications and ensure their products meet the outlined quality standards and compliance requirements, which include passing designated testing criteria as specified in the tender documents.

The tender encourages participation from Micro, Small, and Medium Enterprises (MSEs) by offering special provisions that may facilitate exemptions from some eligibility criteria. This is part of a broader initiative aimed at promoting local industries and compliance with 'Make in India' policies, allowing MSEs to contribute effectively to government procurement processes while ensuring alignment with local content rules.